NAME OF THE MEDICINAL PRODUCT

Tobramycin 1 mg/ml solution for infusion
Tobramycin 3 mg/ml solution for infusion

COMPOSITION

Tobramycin 1 mg/ml:
1 ml of solution contains 1 mg of tobramycin.
1 bottle of 80 ml contains 80 mg of tobramycin.

Excipient with known effect: 283 mg sodium (as chloride) per 80 ml bottle.
Excipients: Sodium chloride, water for injections, sulphuric acid (for pH adjustment).

Tobramycin 3 mg/ml:
1 ml of solution contains 3 mg of tobramycin.
1 bottle of 80 ml contains 240 mg of tobramycin.
1 bottle of 120 ml contains 360 mg of tobramycin.

Excipient with known effect: 283 mg/425 mg of sodium (as chloride) per 80 ml/120 ml bottle.
Excipients: Sodium chloride, water for injections, hydrochloric acid (for pH adjustment).

THERAPEUTIC INDICATIONS

For the treatment of severe infections due to bacteria susceptible to tobramycin when less toxic antimicrobial agents are not effective. Under these conditions, Tobramycin 1 mg/ml solution for infusion or Tobramycin 3 mg/ml solution for infusion may be used in nosocomial lower respiratory tract infections including severe pneumonia; exacerbation of lower respiratory tract infections in patients with cystic fibrosis; complicated and recurrent urinary tract infections; intra-abdominal infections; skin and soft tissue infections, including severe burns.

Tobramycin 1 mg/ml solution for infusion or Tobramycin 3 mg/ml solution for infusion usually is given as a combination treatment, predominantly together with a beta-lactam antibiotic or with an antibiotic effective against anaerobic bacteria especially in life-threatening infections due to unknown bacteria, in mixed anaerobic/aerobic infections, in systemic pseudomonas infections, and in low-resistance immunocompromised - mainly neutropenic - patients.

Considerations should be given to official guidance on the appropriate use of antibacterial agents.

CONTRAINDICATIONS

Hypersensitivity to the active substance or other aminoglycosides or to any of the excipients; myasthenia gravis.

UNDESIRABLE EFFECTS

Tobramycin shows ototoxic and/or nephrotoxic effects. Renal impairment is uncommonly observed in patients treated with tobramycin and is usually reversible upon withdrawal of the drug. Toxicity occurs more frequently in persons with renal failure, in patients that have other ototoxic or nephrotoxic substances administered, in long-term and recurrent treatment and/or in persons that exceed the recommended dose. Ototoxic risk may increase with older age and dehydration.
The adverse reactions considered at least possibly related to treatment are listed below by body system organ class and absolute frequency.

Undesirable effects are listed according to their frequencies as follows:

Common: (≥ 1/100 to < 1/10)
Uncommon: (≥ 1/1 000 to < 1/100)
Rare: (≥ 1/10 000 to < 1/1000)
Very rare: (<1/10 000)
Not known: (cannot be estimated from the available data)

System organ class

Infections and infestations
Not known: Superinfection with tobramycin-resistant pathogens

Blood and lymphatic system disorders
Common: Eosinophilia
Uncommon: Leukopenia
Rare: Anaemia, granulocytopenia, thrombocytopenia, leukocytosis

Immune system disorders
Rare: Hypersensitivity reactions including pruritus, drug-associated fever and skin affections as described under “Skin and subcutaneous tissue disorders” below
Very rare: Serious hypersensitivity reactions including skin affections as described under “Skin and subcutaneous tissue disorders” below and systemic reactions up to anaphylactic shock

Psychiatric disorders
Rare: Mental confusion, disorientation

Nervous system disorders
Uncommon: Headache
Rare: Lethargy
Not known: Paraesthesia, skin tingling, muscle twitch, convulsion (signs of neurotoxicity), drowsiness respiratory paralysis, tremor, balance disorder, neuromuscular blockade

Ear and labyrinth disorders
Common: Cochlear and vestibular damage (in patients with renal impairment)*
Uncommon: Cochlear and vestibular damage (in patients with normal renal function)*
Not known: Dizziness, vertigo

Vascular disorders
Common: Thrombophlebitis
Not known: Hypotension

Gastro-intestinal disorders
Uncommon: Nausea, vomiting
Rare: Diarrhoea

Skin and subcutaneous tissue disorders
Uncommon: Allergic skin exanthema
Rare: Skin reddening
Very rare: Toxic epidermal necrolysis, *Stevens-Johnson* syndrome, erythema multiforme

Renal and urinary disorders
Common: Impaired renal function (in patients with renal impairment)
Uncommon: Impaired renal function (in patients with normal renal function)
Very rare: Acute renal failure (symptoms may include progressive increase in serum creatinine, in urea nitrogen and residual nitrogen levels, oliguria, cylindruria and progressive proteinuria
Regular monitoring is required.

General disorders and administration site conditions
Common: Pain and local reactions at the injection site
Rare: Fever

Investigations
Common: Aspartate aminotransferase (AST) increased, alanine aminotransferase (ALT) increased
Uncommon: Alkaline phosphatase increased, lactate dehydrogenase increased, serum bilirubin increased

Metabolism and nutrition disorders
Rare: Hypocalcaemia, hypommagnesiaemia, hyponatraemia, hypokalaemia

* Both the vestibular branch and the auditory branch of the eighth cranial nerve may be affected. Symptoms include

giddiness, dizziness, hissing and whistling sounds in the ear, and a reduction in auditory perception. The loss of auditory perception is generally irreversible and manifests initially as a loss of high tone acuity.

Tobramycin 1 mg/ml solution for infusion or Tobramycin 3 mg/ml solution for infusion contains sodium. Sodium containing solutions should be used with great care when there is a risk for sodium retention or for complications due to sodium overload.

WARNINGS

Keep out of the sight and reach of children.
For single use only. Unused solution should be discarded. Only clear solutions free from particles should be used.

NOTE

Prescription only
Not all products are registered and approved for sale in all countries or regions. Indications of use may also vary by country and region. Please contact your country representative for product availability and information.

B. Braun Melsungen AG, 34212 Melsungen, Germany, 09/2021